In this paper,we summarize the major problems existing in establishing gastric cancer patient-derived xenograft (PDX) models and its solutions,and introduce its advantages on screening targeted drugs.As many previous research emphasized on individual characteristics too much,we argue that we should pay more attention to the generality of what we are studying in order to analyze the genotype of PDX models before taking a targeted therapy.